SURVEILLANCE OF SUSCEPTIBILITY OF CLINICAL ISOLATES TO PANIPENEM BETWEEN 2000 AND 2003

• Published in: Japanese journal of antibiotics Vol. 58; no. 3; pp. 231 - 258
• Main Authors: ABE, TOMOMI, KOGA, TETSUFUMI, SATO, YUKI, ITO, KAZUYOSHI, TOCHIKAWA, YUKO
• Format: Journal Article
• Language: Japanese
• Published: Japan Japan Antibiotics Research Association 01.06.2005
• Subjects: Adolescent; Adult; Anti-Bacterial Agents - pharmacology; Bacteria - drug effects; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Thienamycins - pharmacology
• ISSN: 0368-2781; 2186-5477
• DOI: 10.11553/antibiotics1968b.58.231

For the post-marketing surveillance of panipenem/betamipron (PAPM/BP, Carbenin®), MICs of injectable β-lactam antibacterials including PAPM against clinical isolates from 15 medical institutions all over Japan are measured yearly and the incidence ratesof resistance in various species are also evaluated. In the first surveillance from June 2000 to March 2001, 1,356 isolates of 28 species weretested, 1,221 isolates of the same 28 species were tested in the second surveillance from April 2001 to March 2002, and 1,403 isolates of the same 28 species were tested in the third surveillance from April 2002 to March 2003. No remarkable changes in the activity of PAPM were observed in these surveillances spanning three years. The activity of PAPM in this study was comparable to that in the studies conducted before Carbenin® was launched. This result suggests that PAPM still maintains potent activity. In these surveillances spanning three years, the incidence rates of resistance in various species were as follows (2000.6-2001.3→2001.4-2002.3→2002.4-2003.3): methicil lin-resistant Staphylococcus aureus (39.3%→43.9%→47.3%), penicillin-intermediate Streptococcus pneumoniae (48.9%→44.2%→25.7%), penicillin-resistant S. pneumoniae (PRSP, 13.8%→26.3%→43.2%), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (0.9%→0%→1.4%), ESBL-producing Klebsiella pneumoniae (3.4%→1.3%→3.1%), β-lactamase-producing Haemophilus influenzae (19.2%→8.9%→2.9%), β-lactamase-negative ampicillinresistant H. influenzae (BLNAR, 22.1%→30.7%→33.0%), and metallo-β-lactamase-producing Pseudomonas aeruginosa (1.0%→4.4%→1.0%). PAPM showed the most potent activity among tested drugs against PRSP, whose incidence rate increased notably.BLNAR, whose incidence rates also increased, exhibited low susceptibility to all tested drugs and metalloβ-lactamase-producing P. aeruginosa also exhibited high resistance. The findings of this surveillance indicate that it is necessary to pay careful attention to the trends of resistant bacteria such as PRSP, BLNAR, and metalloβ-lactamase producing strains.